Clinical Trial

Seladelpar in Adult Liver Transplant Recipients With Ischemic Cholangiopathy (SELIC).

Study acronym: SELIC
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A prospective, open-label, single-arm, investigator-initiated study (SELIC) to evaluate the efficacy and safety of seladelpar in adult liver transplant recipients with Ischemic cholangiopathy (IC).
Protocol Amendment History 2 changes
critical Phase changed: not specified -> Phase 2 2026-04-10
notable Primary completion pushed: 2027-06 -> 2027-09 2026-04-10
Trial Details
NCT Number NCT07305363
Lead Sponsor University of California, San Diego
Conditions Liver Transplant; Complications, Ischemic Cholangiopathy
Enrollment 10 participants
Start Date 2026-05
Primary Completion 2027-09 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-09